Upcoming Value Driving Events

Regulatory/Commercial

• Targretin caps / Panretin gel Europe launch 4Q01

• ONTAK MAA submission 4Q01

• AVINZA NDA approval / launch 2Q02

• ONTAK MAA CPMP recommendation 2H02

Clinical

• ONTAK B-cell NHL interim Phase II data 3Q02

• ONTAK CLL interim Phase II data 1H02

• Targretin gel atopic dermatitis interim Phase I/II data 3Q02

• Targretin caps NSCLC Phase III accrual ? 40% 2H02

• Data publication from Phase II/IV clinical trials 2H02

Targretin: psoriasis, combo studies NSCLC

ONTAK: other T-cell NHL, GVHD

?

?

?

?

Previous slide

Next slide

Back to first slide

View graphic version